NoNO Inc.: federal grants and contributions: 5 agreements; $2.0M value; 1 departments; 3 programs.
Assay record ASY-CA-1FSOX0O1R5 · Cite as: Assay Systems, “NoNO Inc.: federal grants and contributions”, https://assay-systems.com/register/ca/grants/r/nono-inc/
NoNO Inc. has developed and autoinjector compatible PSD95 inhibitor to provide neuroprotection that can be administered by any caregiver at home, enroute to the hospital or immediately upon arrival in the emergency department.
This proposal focuses on translating academic discoveries into new treatments for stroke recovery and chronic neurological diseases that constitute massive socioeconomic burdens in Canada and worldwide. It provides a foundation for a biotechnology industry in Ontario to address these issues and build wealth in our province.
The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.
The funding provided from the IAP program is to assist innovative, early stage small-and medium-sized enterprises that are unable to access existing COVID-19 business support.
The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.
Contains information licensed under the Open Government Licence – Canada. Source: Government of Canada proactive disclosure of grants and contributions (open.canada.ca, dataset 432527ab-7aac-45b5-81d6-7597107a7013), 1,327,352 rows as published, collapsed to one agreement per agreement number (per reference number where none is given) at its latest amendment, which carries the full agreement value. Years are the agreement start year. Agreements with individuals are counted but not named.